Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C

Authors

  • M. Rumi,

    1. Hepatology Unit, San Giuseppe Hospital, Università degli Studi di Milano, Milan, Italy
    Search for more papers by this author
  • A. Aghemo,

    1. A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione, IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
    Search for more papers by this author
  • G. M. Prati

    1. A.M. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione, IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
    Search for more papers by this author

Mariagrazia Rumi, Hepatology Unit, San Giuseppe Hospital, Università degli Studi di Milano, Milan, Via San Vittore 12, 20122 Italy. E-mail: mariagrazia.rumi@unimi.it

Abstract

Summary.  Standard of care for patients with chronic hepatitis C is pegylated interferon (pegIFN) combined with ribavirin (Rbv). It results in persistent viral eradication and prevents the progression of liver disease and the associated complications in about 50% of treated patients. Currently, two PegIFNs are available that differ significantly in terms of pharmacokinetic and pharmacodynamic profiles as a consequence of different pegylation chemistries. While the registration trials of the two therapeutic regimens demonstrated the superiority of each PegIFN vs the native IFN α2b, the superiority of one regimen over the other in terms of treatment efficacy remains unknown. Retrospective cohort studies and randomized prospective head-to-head trials have attempted to resolve the considerable controversy over this issue and support evidence-based treatment decisions.

Ancillary